1st Jun 2015 07:36
LONDON (Alliance News) - Omega Diagnostics Group PLC on Monday saw its shares rise in early trade after it said its Visitect CD4 infectious disease product appears to be capable of meeting its targets and said it has made progress on its allergy development.
Omega shares were up 15% to 24.70 pence in early trade Monday, one of the best performers in the London Main Market.
Omega said testing on Visitect devices has continued in recent weeks, with the aim of optimising the performance of the product and identifying a suitable in-house manufacturing process. Omega said it has now made three pilot batches of the devices, all of which have yielded comparable results and which have demonstrated the product is capable of meeting its performance design targets in comparison to flow cytometry when tested on HIV-positive patients.
Omega has now selected in-house manufacturing processes for the product which are scalable and which will be subject to verification and validation leading to the release of Visitect CD4 devices for re-evaluation in the field. Omega said it remains confident on the commercial potential of the devices and will provide further updates on their development in due course.
Elsewhere, the company said its Allersys allergy development programme has continued and said it will present data on the programme at the European Academy of Allergy and Clinical Immunology annual meeting this coming weekend.
It said it has produced commercial quantities for 27 allergens and associated reagents, all of which have passed internal quality control procedures and will be used in beta evaluations at sites in Spain and Italy, planned in June and July, respectively.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
ODX.L